SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brander who wrote (3097)3/27/1998 9:35:00 AM
From: Doug Shapiro  Read Replies (1) of 7041
 
I think that the FDA will compare it to the oral gold standard as they do in cases where someone claims to have something effective for a particular ailment. There is no current oral standard by which to compare so Vasomax is in good shape if it can be the first to market.

Drugs are denied because they offer little therapeutic advantage over existing drugs and are considered less safe. If however there is a drug available with a high safety profile and minimal side effects
the FDA will compare any newcomer and demand to see at least a similar safety profile or dramatic improvement in efficacy before approving it for sale.

Doug
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext